<SEC-DOCUMENT>0001299933-12-001787.txt : 20120730
<SEC-HEADER>0001299933-12-001787.hdr.sgml : 20120730
<ACCEPTANCE-DATETIME>20120730171524
ACCESSION NUMBER:		0001299933-12-001787
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120726
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120730
DATE AS OF CHANGE:		20120730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STEMCELLS INC
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		12994471

	BUSINESS ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		6504753100

	MAIL ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_45671.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> StemCells, Inc. (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	July 26, 2012
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	StemCells, Inc.
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Delaware
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	000-19871
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	94-3078125
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	7707 Gateway Blvd, Suite 140, Newark, California
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	94560
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	510.456.4000
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 8.01 Other Events.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On July 26, 2012, StemCells, Inc. (the "Company") issued a press release announcing an award to the Company of up to $20 million by the California Institute for Regenerative Medicine (CIRM) under its Disease Team Therapy Development Award program (RFA 10-05).  The award is to fund preclinical development of the Company's HuCNS-SC product candidate as a potential treatment for cervical spinal cord injury, with the aim of filing an IND with the FDA within four years.  Funding to companies under RFA 10-05 will be structured as loans, in accordance with mutually agreed upon terms and conditions and CIRM regulations. The Company will evaluate its HuCNS-SC cells as a potential treatment for cervical spinal cord injury in collaboration with researchers at the University of California, Irvine.   <br><br>A copy of this press release is attached hereto as Exhibit 99.1.
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 9.01 Financial Statements and Exhibits.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
(d) Exhibits<br><br>Exhibit 99.1 Press Release, dated July 26, 2012, announcing a funding award by the California Institute for Regenerative Medicine.  <br>
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><P ALIGN="LEFT" STYLE="FONT-SIZE: 10PT"></P><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	StemCells, Inc.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	July 30, 2012
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	/s/ Kenneth Stratton
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: Kenneth Stratton
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: General Counsel
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
July 26, 2012 press release
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 11pt"><img src="e36707-122121731650fb014f_1.jpg">
</FONT>

<P align="center" style="font-size: 11pt"><B>STEMCELLS, INC. AWARDED $20 MILLION FROM THE CALIFORNIA INSTITUTE<BR>
FOR REGENERATIVE MEDICINE</B>



<P align="center" style="font-size: 11pt"><I>Award to Fund IND-Enabling Activities for the Company&#146;s HuCNS-SC&#174; Neural Stem Cells<BR>
in Cervical Spinal Cord Injury<BR>
Decision on Funding Alzheimer&#146;s Program Deferred to CIRM&#146;s September Board Meeting</I>



<P align="left" style="font-size: 11pt"><B>NEWARK, CA (July&nbsp;26, 2012) </B>&#150; StemCells, Inc. (Nasdaq: STEM) today announced that the California
Institute for Regenerative Medicine (CIRM)&nbsp;has approved an award to the Company and its
collaborators for up to $20&nbsp;million under CIRM&#146;s Disease Team Therapy Development Award program
(RFA 10-05). The award is to fund preclinical development of StemCells&#146; proprietary HuCNS-SC&#174;
product candidate (purified human neural stem cells) as a potential treatment for cervical spinal
cord injury. The award will provide funding over a maximum four-year period, with the goal of
filing an investigational new drug (IND)&nbsp;application to begin clinical testing in that time. CIRM
deferred a decision on the Alzheimer&#146;s disease application submitted by StemCells and referred the
application back to CIRM&#146;s Grants Working Group for further consideration. CIRM is expected to
review the application again at the next meeting of its governing board currently scheduled for
September 6<sup>th</sup>.


<P align="left" style="font-size: 11pt">&#147;We understand that this was a very competitive process and we are extremely grateful to CIRM for
its support,&#148; commented Martin McGlynn, President and CEO of StemCells, Inc. &#147;We view this
decision by CIRM as a strong vote of confidence in our neural stem cell technology and the world
class team of scientists and clinicians who will be collaborating to translate this exciting
research into potential treatments and cures for patients with spinal cord injury. We are
currently conducting a Phase I/II trial in thoracic spinal cord injury. This funding now allows us
the opportunity to expand testing of our cells for cervical spinal cord injury, the most common
form of spinal cord injury.&#148;


<P align="left" style="font-size: 11pt">StemCells will evaluate its HuCNS-SC cells as a potential treatment for cervical spinal cord injury
in collaboration with a team led by Aileen Anderson, Ph.D., Associate Professor in the Departments
of Physical Medicine and Rehabilitation, and Anatomy and Neurobiology at University of California,
Irvine. Dr.&nbsp;Anderson&#146;s laboratory has a long history of collaboration with StemCells in spinal
cord injury, including the studies which led to the world&#146;s first clinical trial for a neural stem
cell therapeutic in chronic spinal cord injury. This Phase I/II clinical trial, currently underway
in Zurich, Switzerland, recently reported positive safety data from the first cohort of treated
patients, and continues to enroll patients from Europe, the United States and Canada.


<P align="left" style="font-size: 11pt"><B>About Spinal Cord Injury</B>


<P align="left" style="font-size: 11pt">Spinal cord injury affects approximately 1.3&nbsp;million people in the United States, for which there
are no effective treatment options. Moreover, spinal cord injuries are a significant financial
drain on the public health system. Cervical spinal cord injuries represent approximately half of
all spinal cord injuries, for which lifetime healthcare costs range from $1.8 to $3.3&nbsp;million per
patient, depending upon severity of the injury.


<P align="left" style="font-size: 11pt"><B>About CIRM</B>


<P align="left" style="font-size: 11pt">CIRM was established in November&nbsp;2004 with the passage of Proposition 71, the California Stem Cell
Research and Cures Act. The statewide ballot measure, which provided $3&nbsp;billion in funding for stem
cell research at California universities and research institutions, was overwhelmingly approved by
voters, and called for the establishment of an entity to make grants and provide loans for stem
cell research, research facilities, and other vital research opportunities. A list of grants and
loans awarded to date may be seen here:
<U>http://www.cirm.ca.gov/for-researchers/researchfunding</FONT><FONT style="font-size: 9pt"></U>.
</FONT>

<P align="left" style="font-size: 9pt"><FONT style="font-size: 11pt">The two applications submitted by StemCells, Inc. under CIRM&#146;s RFA 10-05 for cervical spinal
cord injury and for Alzheimer&#146;s disease, as well as the feedback on each application from CIRMS&#146;s
grants working group, can be viewed on the CIRM website at
<U>
http://www.cirm.ca.gov/research-summaries-rfa-10-05-cirm-disease-team-therapy-development-awards</U>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
</FONT>

<P align="left" style="font-size: 11pt"><B>About StemCells, Inc.</B>


<P align="left" style="font-size: 11pt">StemCells, Inc. is engaged in the research, development, and commercialization of cell-based
therapeutics and tools for use in stem cell-based research and drug discovery. The Company&#146;s lead
therapeutic product candidate, HuCNS-SC&#174; cells (purified human neural stem cells), is currently in
development as a potential treatment for a broad range of central nervous system disorders. &nbsp;In a
Phase&nbsp;I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in
children, the Company has shown preliminary evidence of progressive and durable donor-derived
myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting
a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and recently reported
positive interim safety data for the first patient cohort. The Company has also initiated a Phase
I/II clinical trial in dry age-related macular degeneration (AMD), and is pursuing preclinical
studies in Alzheimer&#146;s disease.&nbsp;StemCells also markets stem cell research products, including media
and reagents, under the SC Proven&#174; brand. Further information about StemCells is available at
<U>http://www.stemcellsinc.com</U>.


<P align="left" style="font-size: 11pt"><I>Apart from statements of historical fact, the text of this press release constitutes
forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the
Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created therein.
These statements include, but are not limited to, statements regarding the prospect of the
Company&#146;s HuCNS-SC cells to restore lost memory in animal models of Alzheimer&#146;s disease; the
potential of the Company&#146;s HuCNS-SC cells to treat a broad range of central nervous system
disorders such as Alzheimer&#146;s disease and spinal cord injury; the prospect of initiating a clinical
trial in Alzheimer&#146;s disease or cervical spinal cord injury; the timing and prospects for funding
by the California Institute for Regenerative Medicine; and the future business operations of the
Company, including its ability to conduct clinical trials as well as its other research and product
development efforts. These forward-looking statements speak only as of the date of this news
release. The Company does not undertake to update any of these forward-looking statements to
reflect events or circumstances that occur after the date hereof. Such statements reflect
management&#146;s current views and are based on certain assumptions that may or may not ultimately
prove valid. The Company&#146;s actual results may vary materially from those contemplated in such
forward-looking statements due to risks and uncertainties to which the Company is subject,
including the fact that additional trials will be required to demonstrate the safety and efficacy
of the Company&#146;s HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to
whether the results of the Company&#146;s preclinical studies in Alzheimer&#146;s disease or spinal cord
injury will be replicated in humans; uncertainties about the prospect and timing of entering into
the agreements necessary to receive funding from CIRM and whether the Company will satisfy, and
continue to satisfy, all preconditions for such funding; uncertainties regarding the Company&#146;s
ability to obtain the increased capital resources needed to continue its current and planned
research and development operations; uncertainty as to whether HuCNS-SC and any products that may
be generated in the future in the Company&#146;s cell-based programs will prove safe and clinically
effective and not cause tumors or other adverse side effects; and other factors that are described
under the heading &#147;Risk Factors&#148; in the Company&#146;s Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2011, and in its subsequent reports on Forms 10-Q and 8-K.</I>


<P align="left" style="font-size: 11pt">CONTACT:


<P align="left" style="font-size: 11pt">Rodney Young
<BR>
StemCells, Inc.
<BR>
Chief Financial Officer
<BR>
(510)&nbsp;456-4128


<P align="left" style="font-size: 11pt">Ian Stone
<BR>
Russo Partners
<BR>
(619)&nbsp;308-6541



<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>e36707-122121731650fb014f_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 e36707-122121731650fb014f_1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!4`:4#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BB@\>I^
ME(#F@!:**3.#C!^O:@!:*/7KQ_GBB@`HHHH`****`"B@'/(HH`**0G&.#SZ=
MOK2T`%%%%`!1110`44F1G&>:,\XP?KVH`6BBB@`HHHH`3G/;'ZTCLJ*S.P50
M"69C@``9))[8%1W$\-M#-//*D,,,3RRS2,$CCCC4L[N[8551068D@``D\"OP
MR_;*_;CU7QO>:Q\+OA)J=UI7@FVDET[Q!XILI7M=0\5/&Q2\M-.N(F2XM/#[
MLK6\K(T<^K1"19<:?.T,_P`'X@>(61>'F3RS/-JGM*]7FIY?EM*4?K6/KI7Y
M*:=^2E"Z=:O).-*+O:4G&$O#S_/\#P]@GB\7)RG*\</AX->UQ%1*_+&_PQ6C
MG-Z13ZMI/[?^/'[?OPE^$DEYH'AG=\1O&=L[0R:;H]RD.AZ=,"5(U37C'/#Y
MD;9S::=!?W&]?+N/LBNLU?F3XZ_X*'_M&>+9IUT76M+\"6,A816OA[38);B.
M,X&UK_55OY7..CHD9#$LA7`QYW^SU^R9\3OVA;[[3H]K_P`(_P"#+>;;J7C7
M6(918-(,-):Z3!\LNLW^&#.D#+;6X(-W=0%XDE_9'X5_L"_`'X<16USJOAP?
M$/7HU7S-4\9!-2L0^!O^S^'6SHJ)N7>C75I>7$9X6X`.*_FW!XGQT\8I2QV`
MQO\`J7PQ6D_J]2G4JX&-2BFK>RJ4HO,,7-Q?\52I4)--*4=G^<4*O'/%[=>A
M6_L3*YO]W*,IT.>&UX2@GB:ST^).%-O1-(_#F;X^?M%>(KII8_BU\6;R?HT>
MD>+?$MJ@+`D?Z+I%Y;P`G:2,1#`4]@:DA^//[1GARY$\OQ7^+5I-E<#6/%?B
M:YB+<L`+;5[N>`E@"2IB.]1R&`K^G_3O#'AC2(([/2_#^BZ=;0#9#!9:586L
M$2J,!8XX((T0`<`*HXXZ5)=^'?#^HQ26]]HND7MO*I26&ZTZSN$D0@@JZ2PL
MK`],$$%?H*]U?1SXHY/:OQ3S98WXU-4,;R*IH_B_M55'KHIZ.VO+T.__`(A[
MFG+=\5X[VV_-R5W&ZMU^N7]'O;H^G\^/@7_@H=^T9X2FA76=;TOQW81$"2V\
M1:;!'<R(I7"B^TI;"56V`KO99&).]RS#YOTS^`_[?_PH^+<MKH'BD-\-O&$[
M1Q1V6LW<4V@ZG,YV)'I6N[8(_.D;'^B:C;V4H+!('O`CR#L/BA^PO^SY\3(K
MB:+PA;>"-<</Y6L^"4CT,>:V6+W6CVR+HEX7D.^:273Q=2DG_2D8[J_'G]H_
M]C+XC_L_R-KB,WC#P"TG[KQ1I=K*LNE,3^[A\062^:=/?D"*]226RG8?ZV"5
MA;CR,9+QV\(?^%'$X_\`UXX8P[3Q/M*E7&SI4$]9575C_:&%=MZD9UZ$':\F
MCDK/CKA%?6*E=9[E=/6KSRG6G"FK)N3FOK%)I:\T95*<;:MK?^@/XD?%WX>?
M"70&\2>//$^FZ'IAC9[42RF6\U%@H80Z;90"2ZOIFR-J6T4GWE+;00:_)[XL
M?\%0?$5]<76G_!_PC:Z/IZ,R6_B+Q9_IFIW*@L!-'HMI*MG8JV%VQSWM])M^
M9O*<F)?S*%WX^^)6J^'_``^;SQ1XWU>*"WT+PWI<]YJ.N75O:(Q%MINEP3R7
M#6UK$SL5@MQ'!$,L0J@D?JE\"_\`@F6)[6Q\0?'/6IHY)XH[@^"/#EP(WMPX
MW_9=6UQ0Q,Z@A+B+2UV(P=(K^7B08R\4/%?Q;Q<LN\.LL?#V54E".,S*4X.=
M*4E'G=;,:E/V=*SYN2CA:4L0X)/63L9OB?BKBVL\-PYAO[.PL%%5L7)IRBVE
MS*>(E'EAK?EA2@ZKCKNSX1\3?M@?M)^+))&OOBQXHL(Y"0EKX=N(_#\,2M_#
M$VCPVMUU)*L\\D@XP_%<J/BU^T@T)N/^%F_&\P8R9_\`A-/';0@`A=WFC4PF
M`?ESG`)P3UK^DCP+\!/@U\-K6"V\&?#CPIHQAC""]72+6[U>8`$9N]9ODN=6
MO7P3\]W>S,`2H(7BO3/[+TK;M&G6&SGY/L=OM/MM\O'7V]Z]JC]'KC3'1^L9
MYXHYF\=-?O(T%C\53A-I.T:]?'T)3BM5_!IZ)6MLNZGP#G=9*IC>*L9[>6LE
M!XFK!2TVG/$TW)?]N1TMIV_F<\*_M??M)>%)8_LGQ7\47J0N%DM/$4Z>($DV
MX!BG?6(KJ[!RI#%;B.3(;+9+9^X?A/\`\%+O$<$MM8?%CPC;:S9-M6;7?"96
MRU.($@>:VDWLWV&\]TAO=/*@[@TA&T_J'XR^"WPF^(%M):>,OA]X3UQ9(VC\
M^ZT6Q6^A5NIL]3AABU"RD]);2ZAE7G#BOS[^+_\`P3>T66*[UCX*ZO-I-V@D
MFB\)>(+N6[TV<@EUMK#69F>]M'(^2$ZBUXA8*LUPBNTL>=3P\\;>`D\;PQQG
M7XGP=#6678BI5E5E!=(8#'U,31E&WV:&*C5DW:,'N1/A_C7(G[;*\YJ9I1AK
M+#U93E.25OAH8B=6#VU4*L92>BCWYKQK_P`%#?%NNW4UK\.?#5GX;TSS-L&I
M:\RZGK$\6?EE>TA>/3[%F7K");_8P)^T/G`\XB_:`^,WB>96U'X@>(1YN[;#
MIER-*1=X("(-+2U<XSA-SNX/W6)&:^B_@O\`\$^=+TNVL]5^+NKOJFH,D<S^
M&=!N9+?3;9B%/V:\U95CO;QD'RR_8A91A\K%/-&HEE^_/"_PS\`>#+:.T\,>
M$/#^CQQJ$+VFF6HN90!@-<WLD;WEU+@#,US/-*V,%R`,?0Y-P9XM<4\N8\5\
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M^15\/:Q<:G`IN4C\S:"6CRN>,\J21D^Q'TKI:R-.T>#3&/V9G\HC`C<EBO7A
M6/)&,#G)XZUKU^AX=58THJL^:HDDY=]%KT>]]]>Y]!34U%*;O);OOIY!1116
MQ84444`%%%%`!129`ZG%`8'H1S[T`+13=P'4X-%`'A?[2'[1_P`)_P!E'X1>
M*OC;\:?$D/AGP/X4MXVGG""YU+5M1NG\G3-!T'3E99M4US5K@BWT^P@^:1R\
MLC16\,\T7\>?[2W_``<P_M+>+]9U/3/V8_A]X%^$?@])Y8M-\2>,M,;QUX_N
MK=)"(+IH+B\@\'Z2TR\S64VB:^5R@CO4(<-L?\'./QW\3:]^T'\'?V>H-3O(
M/!/@'P$/']]HL<TB66H^,?%M]?6,.K7<"[([B?3-!L$L=->42M9K?ZKY+H+^
M=6X/_@@A_P`$SO@5^V)/\4?CC^T+IQ\<^$_A=K^D^$O#7PR.H2VFCZGXBO[%
M-:N==\6)830W^H:?969@MM-T5Y[;3[R:>[FU**_@BA@7^F>"^#.#.&N`X>(?
M&N"EG#Q*C6P>`<?:T84ZM?ZOA:4<.YPHUJV(FN><\0W2IPDO=7*V_P"?.+.+
M.*<_XR?!/"N+661H3E2Q&+C/V=6I.G25;$5'6474ITJ47RQC22G.47[S32/D
M;3/^"^'_``51T_4([R[_`&D=/UJV1V9M)U3X+_`N'3Y@S`A'ET;X;Z1J@1>5
M!BU.-^?F<GD?T(_\$=/^"QG[1W[>'QDU;X&_&'X6>`/^)!X$U/QC?_$[P(NM
M:!':KIMWING6=EJWAK4]0U^VEO=:N+\LMSI^I:?;*UO<-%IL42K&OZI:S_P2
MS_X)YZ]I+:+J/[(WP5%FT7DJ;+PE9Z;=PJ(C"KVU_8?9KVWF2-B$GAG25"=R
MN&P:H_L??\$S/V8OV&/B'\4OB!^S[I/B;0G^*NGZ'I=]X=UO7W\1:1X9L=&N
M;R[:T\+W>HVS^((;/4;FZCGO(-8UK63'+;0K9RVUOF`?.<2\<>%V>\/YGAL!
MP)3R3._9*.5XC#X;"4*2J2J4XRJ5*N!E0ES4X.4XTZM&K2FXVDTW8]SA_@_Q
M#R?.LOKXSBZIF>5*KS9A1JXG$UIRIJ$FZ<*>+C524Y)1<Z=2$XWNE9:?47[2
M'Q5N_@5^SU\=_C=8Z/;^(KSX._!KXG?%*T\/7=W)I]KKMU\/_!6M^*[?1[G4
M(8+J:Q@U.724LIKN*VN)+:.9ID@E9!&W\F__`!%._$[_`*,\\!_^'=\0?_,/
M7]<_QE^%V@_'#X0_%/X+^*KW5].\+_%WX<^-_ACXDO\`P_/96NO66@^/?#6I
M^%M7O-$NM2L-5T^VU>VT_5;B;39[_2]2LXKQ(9+JPO(%>WD_`K_B&$_81_Z+
M!^UO_P"%Q\&__G#?E^N:^:\/L=X9X3"YC'CW*L9F&)GB*$LNGA7B[4Z"A)5X
MS^K8S"QNZG*US*;M>S2N>_QQ@_$#$XK`/@W'T<'AHX>JL;&K]6]^NZB]DX^W
MP]9V5.Z?*XKNGNO@W_B*=^)W_1GG@/\`\.[X@_\`F'H_XBG?B=_T9YX#_P##
MN^(/_F'KG/\`@J=_P1`_96_8=_8]\7_M!_"OXB?M!>(O&7A_Q5X$T.RTOX@^
M*/ASJGAF6U\4>)+/1K^2ZL_#GPJ\*ZJ\\-M</)9M%K,,<<X5IXKB,&,_C3_P
M3"_92^'W[:_[9GPT_9U^*.M^,O#W@OQGI7CZ_P!2U7P!?Z)I?BBWE\*^!/$'
MBC3TL;SQ%X>\4Z5''-?Z3;PWHN-%N6DM'FCA:WF9)X_WK)^&?!3.^&<TXLP7
M#6*_LK*/K?UMU<3FT,1_L6&HXJLJ=+^TY*;]E5AR^_'FDY+0_&,SX@\6,IS_
M``'#>+SV"S+,?JOU=4Z67SI?[76E0I>TJ?4UR>_!\VCLK/J?MS_Q%._$_P#Z
M,\\!_P#AW/$'_P`P]?KO_P`$EO\`@K5XJ_X*4>*_C1X;\1_!7P_\*8_A5X>\
M'ZW:W6B^,M1\4OK+^*-2URPEM[B*^T'1ELUM%TA9$DC><S&=E94"`M\]?\0P
MO["&?^2P_M;Y]/\`A.?@W_\`.&S_`#X_.OT(_8!_X)4?L_?\$YM>^)/B+X+>
M-/C'XKO?BCI'AW1=?C^*.O>"=9M;.U\,WNIWUC)I">$_A]X*E@GFFU:Y6[:]
MGOXWC2!88H'61Y?R/BW,_!?$</YA1X5R/,<)GTXX?ZAB*\L?[*FUB<.Z_.J^
M8UZ;YL,JT5S4I>]+3EEJOTSAG+_%BCG>!J\19KA\1D\95/KM&G]2YYQ="HJ5
MO986G4TK.FWRS3T=[J]_TUX`_P`/SK\$O^"BO_!>+X+_`+%OQ`U+X*_#;P:W
MQX^+OAY8D\96UKKHT'P3X+U&9%F7P_JWB&*SU*>_\0P6[QRZE8:39W$6DO/'
M8WUW'JD5]I]E^WOQ$UUO"_P_\<^)4=XW\/>$/$FN)(B[WC?2=&O+]'5,C>R-
M`&"Y&XC&>:_RD;"V\9_'KXOV%CY[ZS\0?C)\1K*PBFNI6+ZEXM\?>(X;2`S3
M2%F`N=5U5`6);8C=]HS'@SP#DW&&,SC,.(>>IE.1T:$ZF&C4J4(XBMB/;33J
MUJ3C45&A3P\YSC3G"3<H>\E=/;Q6XSS7AC#99@LDY:>8YM5JJ.(E3C5E2IT7
M1C:E3FG"52I.M&,7.,HQ49^ZVTU_3?\`\13OQ._Z,\\!_P#AW?$'_P`P]'_$
M4[\3O^C//`?_`(=WQ!_\P]?4/@G_`(-=_P!GB/POHP^(G[17QIU#QD;*W;7K
MCP;:^!M%\-?;WB1KF+2;#6O"_B+4UM89B\<,UWJ3RSQA97A@9C&.I_XA>_V1
M/^B^_M(9ZX%Y\,?US\/.G]:^SGF'T<(3E!93BYJ,G'GA_K"X2LTN:+>+3<7:
MZ;2NF^[M\G#`>.TX0G_:5&//&,N64\H4H\R3Y9)89I25[.S:33UT/9_^"5?_
M``6C\8_\%%_VAO&'P1\0_`7PU\+K+PQ\&_$/Q2B\0:-XZU3Q/=7=SH?C7X>^
M$TT>2POO#FD10P7$7C::]:[6Y>2.33XH1`RSO)'^_P#7X_\`_!/_`/X(U_`G
M_@GE\9?$GQJ^&/Q.^+7C3Q!XF^&FL_"^[TKQY<>#Y='@T?6_%'@WQ5<:A;+X
M?\*Z'>#4HKSP786\+2W<EK]ENKP/;O*89(OV`K\/XXK<*5^(*]3@RA4PV1/#
MX54:57ZUSJNJ26);^N5*E?WJMVKRM_*DM#]@X.I<24<DI0XKK1KYPL1B'4J0
M=!IT'.]!7PT(4KJ&CM&_=L8.-QQCOWYZ_P">*_C_`/VM?^#D+XU?"[]HWXG?
M#+X,?!3X7WWP_P#AIX[U_P`$+JWCB[\3:CX@\6/X6U:?2-2U>!]#UC2-/T2U
MU&YL[EM-MVM]6E@M6MYKF224R6Z?UL>.O$47A#P7XN\63NJ0>&?#.NZ_,SX"
MB/2-,NK]RQ*M@8@Y^5O]UNA_R:O&_B"3Q9XT\7>*9I9)Y?$GB?7]=DFE8M)*
M^K:K=WYD=F"EG<S[F)522>0.E?IW@3P5D?%>,S^OGV`AF&&P&&PE/#TJDZT(
M1KXFI5E*I^YG3;E&G1M&\G;G;23LU^>^,?%F;\.8?)J&38V>"KXRMB*M>I3C
M3E-T:$:<81]^$[1E.;<K+7EM>VC_`-/?]@G]KSPY^W)^R_\`#S]HC0=+A\/7
M?B8:QI7BOPG'?IJ,WA/Q=X;U2ZTC6='GG"1.Z3&WM]8TQIX89Y]$U72[N2)/
MM(%?9&3SQVX_+O\`C7\?O_!KW^T"8+O]HC]E_4[K]Q?/I/QG\)6TDB@1WRV]
MKX1\8K!&3O=KNTM/"DTFT;(A8,V-TY-?V`KG&#VX_*OS;Q"X;CPIQ?G.2T8R
MCA*.(5;`J3<O]BQ4(U\/%2E[T_91FZ#E)MN5)MMNY]]P-GT^).%\KS2M-3Q5
M2BZ.,:27^UX=NG6;BM(NHTJO*DDE45DE8^6/VT_VI/#W[&O[-'Q._:'\1Z6V
MNQ>!-(BDTGPZMVM@_B+Q%J=W;Z9H>C+>.DHMDN[^ZB-Q.(I9(K2*XDCBED1(
MW_F(_9Y_X.5OCAXZ^/WP\\&?%7X(?"G3OAEXZ\<:#X1N[KPK>>*[;Q-X8M_$
MNLV>D6VKOJ.IZKJ6G:M'I)NUN+VW_L;3S=PQR-#);N%C?V[_`(.?/VCX]#^&
MWP'_`&6M%U%/[4\=ZYJ?Q7\<644I$]OX6\)C^P_"$-W#G#6FO>([_7+NW8@D
M7'@V0`JI(?\`C3L;Z[TR^LM2L)GM[[3[NVOK*X3A[>[M)DN+:="00'BFC212
M00&49K]W\)_"S(,\X'Q.<9[EJQ>.S6>-66U)U:U.6'P]"+P]&=*,)P2G/%0J
MS4IQES)0WB?C/B1XB9UE7%]#+<HS"6&PF6K"?7:<(4I1KUJKC5K1J.<)-PC1
ME"*2:2;G?5:?Z[BN'`*YVD9!['/3%&"&_P!D\_I_C7FGP8\?V/Q6^#WPI^*&
MDM#)IOQ(^''@CQ[I[02"6!K#Q?X:TWQ!:-#('<21&#4(S'()'#H0P=L[CZ+>
M745E:W-Y.XC@M8);B:1CA8XH8VED=CV544L3Z"OY7Q,'A:E>G6]QX:=6%6_V
M71E*,[^G*S^C:%:-;#TL0G:%6C"LGTY9P4T_N?\`P#\OO^"CO[15]X+\/67P
M9\)Z@UGKGC&S-]XIO+60I=67A;S7C33XW0AX7UR:&6&=U(+Z=!=6^-MTQ7X`
M_8V_9@N/VA?&LEYK@N+;X<>$[BUG\27$1:.36+AF\^#P]:SC:8VO(T)U":)A
M-:V;9C*3S0.OBGQL\>:I\7_C'XT\7RO)<S>(_$\]MHT#,7^SZ5#<#3-`TZ(@
M!2+>PAM(2RA?,D\R=EWR,3_1_P#LY?"?3O@O\(/"'@NTM4AOX--AU'Q%<*FR
M:_\`$>H(D^K75QGYV<3L+>,.6\BUMX+=#Y<2BOXDX<R^7CCXMYOG>;N5?A/A
M:HJ>%P<VW1K4Z5><,%AN57CRXJI3JXO$VLZD%R7Y79?CN7X=\;\68S&XN\\H
MRJ7)1H2UISC";C1I6V2JRA*M5>\DN7;;T<#P9\,O!\KO-H/@KP3X1TB:YN;N
MZGLM$\/Z!HNF0--<WE[=W+V]CI]A:6\<DUU=W,L<,,:R33R@!FK^7+]N/_@Y
M&T3PCK6N_#[]B?P=HWCFZTZ>XTZ7XS^/(;]_",T\,CP3W/A#PI:W&F:AK=LC
MHS6.KZM?66GW>8KN'3[ZR*BX^9?^#@?_`(*5ZUX^^(>J?L1?![7+C3_A[\/[
MB.+XVZOIMTT?_":>-L)./!1:!@6\/>$D,7]JQ2,1J7B*6:WFA2#1HWO?S:_X
M)E_\$HOB[_P4.\27FMB\O/AM\`_"VJ1Z?XM^*=SI;WAU+48Q!<7GA/P-;7#P
M6VL>(X[*:&6^G:1]-\/QWEG<:B)I+BVL;K_6GP_\+N&,BX9I<:>(+I8?+%1I
M5,MRB?-2H4\-HL/*M1I)5*]6O&WU?!4E94^5SC-RY8?NV'PM*C2C.HHQA&,5
M""248Q5N5**MT2LEHEIL>8_$#_@K/_P4<^(^KS:QKG[7OQ@T>665I$LO`6O1
M?#32+=29"D$.E>`+7PW9>5$LA1?.BFED"1O/)-*@DJW\-_\`@KG_`,%'_A?J
MT6K:%^UM\5=?*S)+-I_Q&U2U^)^DW2*1NMY;'Q_9^(4AAE4;':Q:SN%!WPSP
MS`2#^W#X)_\`!&3_`()V?!+P[9:+9?L^^'/B)J=O;I#?>+_BNS>.?$VK3A`D
MUY<R7RPZ/I\EQC=):Z#H^CZ<A.(;*,<5/\9O^"-7_!.SXT>';S1-0_9W\+>`
M[^>W:*S\6?"WS/`WB;2IMI6&[MKG3,Z;>/;D[TM=:TO5=.D(VW%E,A*UZS\6
M_"CVRP7_`!#^D\LO[+ZP\KRCF]GI'G^JVYN7=V]MSJ.JCS>X]/K6'O;V?NZ:
M\L>C73M_EL?E;^PE_P`''?A#XCZ[HGPX_;0\)Z)\+=:U:>VTZQ^+?@I-1;X?
M2:A</'!$WBO0]1N]3U7PI:S2-F;5K?4-6TVU8B2[2PLA+/;_`-/C#0_%VB#!
MTWQ!X<U[3@ZNC6VHZ7JNF7\.Y)(Y$,MM=V=W;R*R.C/%-$X96*MFOX5OCI_P
M;M_M8^#OVA_#GPW^"UY9?$SX.^-+J\N=/^,&L"WT&W\!Z3:21-<6WQ%T^.>=
MTU6WBG2/3WT-+F/Q*Z//96FG[;NTL/[#/V'?V5H/V,?V;O`/P`A^(OB_XH'P
MA;W4EQXG\87*22"\U*5;J]TOPWIZ`C0/!^GW1EC\.Z`UQ?RZ;:.4GU"\G>29
MOSCQ3RCPVCA\NS/@O,:53^UH2>*R*$:E>A3P\HS4JTO;7E@I*:]E/!5^9RNY
M4XPA%\W/BJ>'<;P<6IK6G\47%K5.+NEYIZ;Z'0?!G]E/X4?`[Q%XI\3>$-*D
MDU7Q%J,UQ9W.H[+E_#>E3JC-H.B2,H:&P2?S9/,<M=RPO#;3SRI;(S)^U-^U
MY\!/V-?AM=_%'X^>.;+PIH2/]DTC3(HWU'Q3XKU9E)AT;PKX=M2VH:O?R$`R
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M6/V__:;_`.#F/XZ>*;W4=$_97^%_A/X7^']T\%GXT^(5N?&OC>6+(6&]L]#2
MXM?"6CSC:7,.I6WBF%ED"-&K)N/Y@ZM_P6?_`."G6LZHNK7?[6OC.WND='2#
M2O#/PVT33`8Y6E4'1M'\%V.E2IN8JZ364BRQ@12AXP%K]O\`_@GM_P`&Z'A6
M\\,Z%\5/VZ[[7+[5M9L[74M-^`7AO4+OPW:Z);W$2SQQ_$/Q-8RPZ]=:N5D7
MSO#OA^;0UTB>!H[_`%?4VFFL+3]O;;_@D9_P3=L](.CQ_LB_"62W,?E?:KG1
M[B[U;&T#<-8N+N35!)QGS!=A]Q+;LL2?V3$\:>"G"-:6593PC3S_`.KS5*OF
M,L)A,7"<HM1J.&,S&<JV(::;_=1AAY2UIRY7<]'VN%I/EC!2MNTKZWVN^UNA
M_+/^R=_P<`?\%$[?QWX,^'?BW1O!O[4TWBK7=*\-:5HFH^$]-\'>/=1O=2N8
M+#3[+2=>\!6NAZ(LSR2+Y]WK?A;5'=0T]W>1!9K@_P!T6DS:C=:5IEUJEE'I
MVJ7&GV<VI:=#<_:X;"_FMXY+RSBO!%;_`&J.UN"\$=SY$/GI&)?*CW[!^8WP
M,_X(Z?L/_LX_M&Z;^TK\)/`>N:!XGT71-5T[0_"5_P");OQ#X$T'5]5DME?Q
M=HFFZ['?ZU8>([:P2]TNTVZ])HUI::E<RVFD6]\D%W'^I8Q@8Z=OI7X]XBY]
MP?GV88.OP?D$<DP\<,Y8U^QAA95\34:_=_5:%6IA:<*$8Z5*23JRJ2<G:*OR
M5YTIR3IPY=/>=K7?IMI_PQR_CGQ#)X1\%>+_`!7#;)>R^&/"^O\`B&.SDD,,
M=W)HNE7>HI:O,J2-$EPUL(FE6-S&'+A&(P?Y&?#G_!T%\2M<\0:#HLG[(W@B
MW36=9TO2WG3XL:[(\"ZC?06C3*A\$J':(3%PA90Q7!(SFOZP_C3_`,D<^+'_
M`&37QU_ZC&J5_E/_``__`.1Z\#_]C=X9_P#3U8U]UX*<%\-<68'BRMG^6K'U
M,MA@7@I/$XNA[%UJ.83J:8:O14^:5"D_WG-;ELK)ROMA*5.HJCG%2LXVW6Z?
M9KL?ZU2DE03U(S3J:GW%_P!U?Y"G5^`'$%(QPI/H"?R%+37^XW^ZW\C36Z]4
M-;KU1_'!<_\`!TC\3()[B$?L@^!V$,TL88_%K7@6$;LH)'_"$'!.,^U?V%Z!
MJ)UC0]&U=XA`^JZ5IVI/"KEUA:^LX;IHE<A2XC,I0,54L!DJ,XK_`"1]1_X_
M;[_KZN?_`$:]?ZTW@C_D2_"'_8KZ!_Z:;2OWSQMX,X;X2H<)SR#+E@)9E2S*
M6-:Q.+Q'MGAX98Z+_P!IKUN3E=>J_<Y;\_O7LK=F*I0IQIN$>5RO?5ZZ+NSJ
M****_`CB"OR0_P""H'_!6+X7?\$\/#^D>'+?3(?B/\>_&6FW&I^%?AQ#>O:6
MFDZ,CRVL7BOQIJ$$<LFEZ+-?Q26NF6<8&I:Y-:WRV2I;V-Y=P?K<WW3]/\__
M`%J_S$_^"F7Q<U_XU?MW?M/>,-?OKB\DL?BQXL\$Z4DS,4T_0_`6JW/A'2]/
MM48GR[:WAT@LB`[2\CN/OFOUKP>X'P/&W$E6CFO/+*\KPJQN*H4Y2A+%3G45
M*AAW.-I0I2ES3J2@XS:@HIKF;73AJ2JS?-\,4G;NV]/U/<?C5_P6R_X*0?&C
M6[S4)/VA-:^%^CW#SBQ\*?!RQT_P%I6DV\QS]GMM6LH9_&5\4!"I<ZSXGU.[
MCQF*>(':/,?!/_!67_@H]X`OH=0T3]L'XQZA-#)Y@A\:Z[;?$6QD)()2;3_'
M]CXELYHVVX"/`0@+>5L+$G^L#_@BY_P3B_9:\-_L??"+X[^+/AGX,^*'Q7^,
M&@S>,-6\5>,]&L/%$>B65[?75M8>&=!L-7M[G3]/M;"ULXA?-#:"YNM1:Y:X
MFE6.$)^JGQ'_`&#?V-/BUHTNA>._V9_@UJNGRQ-$!:>!-`T.[@W`_O+74=!L
MM-OK6=228YX+A)8V^9'5@#7Z9F7B?X:9+F6*R*AX<X'%9?E^(JX&>*6%RV$Z
MDJ$W1K3AAZV%E.HN>,N6=;$1J5%:4E%R9T/$4(/D]E=)VO:-M#XN_P"",W[:
M?[17[</[-7B3XH?'S2/!T6H^'_'MQX(\/^)O"FDW>@KXM@TO2;"\U6_U72WN
M[W38-1M;K4(()'T865A('^33K0IABOT*_9H_9J^$W[)/PET?X)_!31;S0?`.
MA:KXEUC3K#4-2NM:OH[GQ1KVH:_>)<:K>E[V^2TEOQINGRWLMQ>1Z38V%M<W
M5U-`]S*5_.O$.-RS'YYFF,R?`1R_*\1C:U7`X)1Y%A\,Y+V=/DC*48.RNX0;
MA%R<8VBDCBG*#FW&"46[I;66FEEIT_K6_P#+]_P<Q_L?>.-3UKX9?MC^#]%N
MM8\'Z5X:7X:?%:>PA,LWA>X@U66]\(>(=12/,@T?5?[2O-$FO-I@T^_M-/CN
M'7^U(37X;?\`!.3_`(*8?&3_`()T?$'5M;\$Z=IOC;X;^-I=.7XC?#37)Y[2
MTUN+3BZ6^J:'JUNLLN@>)K.WFFBM=2^S7UI/$PM]2TZ\A2+R?]*OQ)X;\/\`
MC#0=8\*^*M&TWQ%X<\0:;=Z3K>AZS96^HZ5JVEWT+VUY8:A9722V]U:W,,CQ
M30S1LCHQ!%?S%?MF_P#!M5\,?B!=ZWXV_8]^(,/P@U^Y:>]A^%OC>#4-;^'-
MS<2$O]ATCQ':/<^)?"-MN.8O/T_Q9;H%6W2VMD9KB/\`=?#OQ-X7J\,1X#X]
MPZ>60C+#X7&RISJX9X>=1U:=+$JBG7H5:%63='$TTU%*$G*FX<S_`)^XX\/N
M(*7$,N,.#JS^O2DJ]?"QG&&(A6453J5,/SVIUJ=6"2J4)M<WO64N:R_1K]D[
M_@MK^PK^U2VD:)#\0C\'/B#JA@MQX&^+OV/PS+)J$YCC6RTSQ+]KG\+:J\DS
MB.U$6J17-SNC46D<SF%?UT1XY426-TDCD57CD1@Z.C@,KHRDAE92"&!((((.
M*_RS?VK?V&_VF_V+/$UOX9_:$^&FI>$TU"::+0O%%I-;ZYX+\2^2"Y;0O$^F
MO-IUW)Y.V=[&9[75+>-MMY8V\J2Q)^Z'_!"/_@J[\2/"_P`7O`W[&/Q]\:ZA
MXM^%_C]X_"?P>U_Q1?2:AJO@+QE(@'AGP;'JMWYM]<>%_$<R#0-#L+BXF&BZ
MO<Z38:>D6ES^599\:^"V74LEK\5<"9K_`&MEE*E/%U<%*M3Q;^K07-4G@<71
MTK>QBI.5&K'VKBFE4E-<LM>%/%C'RS6CP[QCE_U#,*E2&'IXJ-.6'M7G[L(X
MK#U/X?M):*I3?)>2]U1U7]LM%`.?_K<T5_.7<_=ULNA^('_!PU_RC'^)G_90
M_A!_ZG>EU_+E_P`$`?\`E*1\!^Y_X1WXR\?]T@\:5_4;_P`'#7_*,?XF?]E#
M^$'_`*G>EU_+E_P0!_Y2D_`;_L7?C+_ZJ#QI7]4>''_)B^/?\7$7_JFP)_-W
M'O\`R>'A#_%D/_JSKG^B41@[@,GZ_K_2G445_*Y_21Y-\=\?\*2^,9Y_Y);X
M_P`],?\`(IZL?PZ5_ET_LJ:[HWA;]J#]FSQ/XBU*ST7P_P"'/CW\'M=UW6-0
ME6WL-*T;2?B%X=O]3U*]N'.V"TL;*WGNKF9CB.&%W/`-?ZC/QW_Y(A\8O^R6
M^/\`_P!135J_RD_`_@[Q!\1/&7@_X?\`A.S34?%7CKQ/X?\`!WAG3Y+JVL8[
M[Q!XGU6TT71K.2]O9;>RLTN=1O;:%[J\G@M;=7,MQ-'$CN/ZI^CM2I5\GXWH
MUZBHT:JP5.K5;25*G/#8Z,ZC<FHKDBW*[=M-=#^<?'*I4I9KPC5HT_:U:<L7
M.G32NZDXU\"XP26K<I62MKKY'^FPO_!37]@#`'_#7'P.X4`_\5QI><@#MYG^
M>E._X>:?\$_^O_#7'P/^O_";Z7T_[^5_$P/^"`G_``5*(!'P"T#!Y'_%YO@Y
MW_[GBC_AP'_P5*[?`+0#_P!UF^#G_P`W%>+/PO\`"=1DX^*>";2;4?KF4.[2
MNEI6OKHN^OH>G#Q#\2&X1_XA]BU&\8N7U7,=%HF_X/9W\N^C/]$X$'D="`1]
M#2TR,%8XU/4(H/U"@&GU_.+W?J?O,6W&+DK-Q3:[-K5?)GPQ_P`%+OB&OPL_
M8'_:T\;"Z^R76G_!3QEIVF3DA0-:\2V)\,:'&29(_P#6ZOK%E"`K"0^9B-7D
M*1M_G>?L+?LQ7G[7O[1.B_`ZR:>%]=\"?&#6X[R`L#8ZGX4^%/C'Q%X7GEV1
M2L]O+XQL/#UE-$$_?1W9A)7S-R_VD_\`!QC\3/\`A!?^"<&O^%(YA'-\8OBS
M\,O`!0%Q*UII6IW?Q0N638K83=\.X()F=HXREQY+.6F2*7\-O^#9?X?)K_[9
MWQ1^(,T'FQ?#SX(:G8V[E`T=MJ'C7Q%HEI%.'W*4F-AI&I6R#:X:*XGSM.,_
MU%X6XJOPMX2\9\4T6J>*EBZKP525FO:X:CAZ%%-.RE_M-9W5VFM%K='\Z^(V
M'AQ%XD\,\/U+RP\:%*&(BND,34JU:DO\2IPT[6W1^;'_``2]^/\`=_LB?\%`
M?@9XW\13R:'H:>.V^%GQ-BN28DLO#/C:=O!^NS:B"R%8?#6H75GXBN%SD2:$
MHVR`&-_],X2*<$=",YXQC&<YS7^:[_P6'_9XN/V8?^"A?QQ\-Z?9/IWA?QGK
M-C\8O`$T<)@AFT#Q]&=6NA8J>##HOB^+Q-X=5U.'ET5W.TL0/[)?AS^W]8V7
M_!'K3_VUKBXM;WQ'X3_9YO%^S74_[K4?BWX8M)O`FGZ1>ROND8:EX^M;*WOI
M56240W,]Q'#)M"-Q^-&5KB;#\"<897#VDN(L+A,KJ<JO?$8F,*^"C-QNE+FJ
MXFDUNG3:^RSI\*<R_P!7JW&'#68S<5DE7$YA3YG_`,N<.Y4<2X1>O*U3HR3Z
M\Z>S/XXO^"S?[00_:(_X*%_'/7K*]:_\.^`-3MOA%X899C-;PZ?X`$VFZDMK
MD`113^)I->O)$4E3=7%Q("QD)KYM_;._98U[]D+XF>$/A=XG2\B\0:K\&OA7
M\0M>@O$"2:?K_CCPQ;:UKFB8!(SH&IS7&BRX`S-8R'YB2Q]8_P""97P/U']K
M3_@H#\"_"/B*.7Q#8WOQ%7XF_$:>]_TG^TM&\)7;^,M??4]P`GBUN\M(["_W
M%3*NI2\DG!_6/_@Z`^'3:'^TO^SQ\3(H5CL_'WP>UOPRTBJ1Y^J_#WQ4;B\8
MML"L4TSQMH<>W>S*J*65`R%_V?!YW1X:XIX)\.<*XJC'AO$O$K1OV^'H4OJC
M>VK6%QM25M6YIM:MK\KQ655<^X=XLXXKJ3J2SS#JC)\UO9UJLGB+?X95\/"S
MM9+331_T:_\`!&?X@O\`$;_@FG^RKJ4\IEN_#?@&3X?7(+F1H4^'^N:KX3TV
M(NP!P-%TK2W5.D2NL0)"9K[>_:`UZ3PS\$OBKKD!99=,\">);E&7J&&E7(!7
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M/V/PAX7U/Q!<_O)!Y<?[G3G^>3]VA^9_E!K^??\`8.GBM_VKOA'),X1&N?%T
M08_\]+CX?^*X84^KRR)&/5F%?M'^WOI=]KG[#7[9&CZ7$]QJ6J_LL_M`:?86
M\13?<WEY\)_%D%O;*7P@-Q*Z0Y)``?.Y>H_EGZ(^#PU3AO,*LU%5,9Q?3PN)
M>TGAZ>&R[DYFO?LOK->SZ-R:U/(\*J=-Y1BZME[2IFLJ<VMW&%##..N]KU:E
MK[7=MV?YDD2^-?CU\7H(BTFM_$+XQ_$6WMDY;?J?B[Q]XCCMX8TWF1U%SJVJ
MI%$K%RBLJ_-MK_43_9A_9_\`!O[+OP'^&GP,\"6<%OH?@#PQI^D/<0Q)`^LZ
MOY2S:[X@O`JC=>ZYJ\EYJ=R[9;?<[,X50/\`,Z_8N\3Z-X)_;&_9,\9^([M;
M#P]X0_:8^!'B?7KYRH2RT;0?BCX6U35+MBS(NVWLK6>9MSJN$.6`YK_4_0Y1
M3URH_E7^F7TC\9B:57A7)Z<94<LA@L3BH0@VJ52O3='#PAR))7PM&RAJ[+$/
M1=?UO&MKV<>GO/UMRVOZ:CJ***_F$\\****`/YJO^#F;XR:AX2_93^%7P?TV
M\:"/XM?%%-0\06\4I1[S0_`.G_VO;6UP@D4RV;:_>Z7>E&1T^V:;9RDJ\*$_
MSG?\$;+3]GRU_;C\`>/_`-I3QQX+\#^`?A/IVJ_$+2KGQSJ5KI^D:EX[TG[-
M#X.@S>8BFGTW4[LZ_;(<M'>:1:3!&"$#]KO^#I'2K]M#_9,UL>=_9<>L?$?2
MW^6/[/\`;YK'0+N/+;?-\[[/!+M4-Y>S<2N[!'\HGPT^$7Q/^,VNS^&?A1X"
M\4_$/Q#:V,NIW&B^$='N];U*'3H9(XIKQ[2RCEE6WCDEB1Y2NQ6=02,BO[:\
M*<HPF+\'IX-X]Y7#-WF\<=F-.5.%3#.IB)X:4U.HXPC*.'IP2E.2Y4[IKIZV
M'2^KVORWOKVOUZ'^E9_P\Q_8"SC_`(:V^!O'/_(\:9C\/FZTO_#S']@/_H[?
MX&_^%QIG_P`77^>1_P`,!_MM?]&K?'/_`,-YX@_^1*/^&`_VVO\`HU;XY_\`
MAO/$'_R)7Q__`!`S@/\`Z+]_^#<J\O\`I]_5_2V7U2E_S\_+R\^OZ^A_J`^&
M?$V@>,_#7A_QCX5U:RU_POXJT32O$GAS7=,G6YTW6M!URP@U/2-6T^Y3Y+BR
MU'3[JWO+2=?EE@FCD'#5M@YY%?,/[$6@ZWX5_8Q_9'\+^)=+OM#\1>&_V9/@
M-H.O:+J=O)::EI&M:/\`"SPKI^J:7J%I*JRVM]I]];SVEW;RJLD,\,D;@,I%
M?3]?R[BZ4,/BL30IS]I3HXBM2A4T]^%.I*$9Z:>]%*6CMKIH>>U9M;V;7W,\
MS^-/_)'/BQ_V37QU_P"HQJE?Y3_P_P#^1Z\#_P#8W>&?_3U8U_JP?&G_`)(Y
M\6/^R:^.O_48U2O\I_X?_P#(]>!_^QN\,_\`IZL:_J#Z.7_(MXZ_Z]Y9_P"H
M^:GH8':IZQ_)G^M4GW%_W5_D*=34^XO^ZO\`(4ZOY7/."FO]QO\`=;^1IU-?
M[C?[K?R--;KU7YC6Z]5^9_D9ZC_Q^WW_`%]7/_HUZ_UIO!'_`")?A#_L5]`_
M]--I7^2SJ/\`Q^WW_7U<_P#HUZ_UIO!'_(E^$/\`L5]`_P#33:5_4GTD/]VX
M%_Z\9Q_Z;R8[\;\%+Y_E$ZBBBBOY://$/((]J_SM_P#@MQ^QIXW_`&8OVR_B
M)X]DT*];X2_'KQ)J?Q"\">*XK:9](;5]:<ZCXJ\*W5\`\,&NZ5JTMW=&SE:.
M6YTZYM[ZVC>$R^5_HDUX]\=/@'\(_P!I3X=:S\*?C9X(T;Q[X'UQ4:ZTC6("
MQMKR$-]DU32[R)H[S2M6L78R6>I6$\%U`Q90YCDD1_T+PVXZK<!9_P#VE["6
M+P.+H_4\QPT)*-2=!SC4C5HMM1]O1G'F@I^[.,IP;CS*<=\/6]C.[5XM6=M_
M)G\)'_!,W_@MC\6?V$]'T[X0>._"Z_&#]GB&\NKFS\/PW::9XZ\"R:A<-<WD
MW@W6+@OIM]ITL\L]S<>&M:AC@GN&5M/UK1<W)NO[!_V2?^"I/[&?[9CV6C_"
M?XJ6.G>/;Q`P^&?CI8_"?CB27;ODMM-TR_F-MKTD2AV8>'[W5#Y<<DP'DJ9*
M_`/]K_\`X-GO$5BVJ^+OV,/BC9:U:_Z1=1?"+XKRMIVIQHI\Q++PY\0K..:P
MOY9%/DVUGXFTK2(T,:O=>))!*WD?S+?%/X1_&G]E_P")UQX*^)WA7Q7\)_B;
MX2O+;4(8+S[1I&KV4\$HFT_6]#U6RE43P>=$L^G:SI-Y)"SQB6VN=Z9'[]C.
M$?"_Q<>(S/AK-%E7$-:$J^)HTU[*K.L[.53&Y77<>?WG:IB,'*,9MN3JU'J=
MKIT,3[T7:3U;6[VWBS_5VHK^7_\`X))_\%J]%\8?!#Q!X$_;*\?P1_$/X7WV
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MHA)9_9)L/`R#XU^'W_!?+_@IKX#TJWT:?XT^'_'UM9HL-M<_$'X;^#=7U6.)
M58!;C6M*TS0]5U-\OO:ZU>[U"]=E4/<L@*'[S*O`WB+/L@RC/<HS+*JW]I85
M8BI@L36J4*F&4IR44ZE.%>%1N"A)IJFXN;B[M:_CF8^,&2Y/G69Y1F67YA3C
M@,0Z%/%4(1JPK\L8<TO9SE3G&TG**:YHOE34O>T_LB_X+`^'/A)X@_X)T?M2
M'XOP:*VF:+\,M;UWP=>ZLD'VK3OB?IT7F_#B70)Y5^T6^MWOB[^R]*@%G)#)
M>VM_=Z9<R#3KV]5O\[_]EFVUV\_:<_9SM?"_F_\`"2W'QV^$<7A\P+.\RZU)
MX_\`#ZZ6\2VQ6X+I>F%E\AEER/D=6PP]J_:K_P""B'[8O[<,FEZ3\>/BKJOB
MO0-/OH[G0OA]X=T;2_#'A"UU$JT<-S'X<\-6-FNL:DOF2+;7^MOJ^IP+*\-O
M=1Q$1C]W_P#@@[_P27^)5O\`$[PI^VQ^T=X+U#P9X9\&K=ZI\$/!'BJR^Q>(
M/$GB.YM+C3;3Q_JF@7:B^TC1M#CN+J\\*#5[:SO]1U==.\2Z?#_9MKI=_?\`
M[#D66Q\'/#W/X<39KA:^.S/ZS/"Y;0K<\/K%;!_5J6&PL:BA.K.J[5,14C3C
M3C!)M6@Y/\LS?,)^*/&^35,ARRO1PN!>'CB,;5I*,G1IXF->I7Q$H<T::@OW
M=&,IN;;LOB2/[)$X5<XS@9]S_C3Z,9_`YHK^,3^KXJR2WLDON1^('_!PU_RC
M'^)G_90_A!_ZG>EU_+E_P0!_Y2D_`;_L7?C+_P"J@\:5_4;_`,'#7_*,?XF?
M]E#^$'_J=Z77\N7_``0!_P"4I/P&_P"Q=^,O_JH/&E?U1X<?\F*X]_Q<1?\`
MJFP)_-W'O_)X.$?\60_^K.N?Z)E%%(02"!7\KG])'E?QT!D^"?Q@CC#.[_"_
MQ\B(BEF=SX5U4!54`EF)(``R22`,FO\`+P_9%U&QTC]JW]F'5-4NX-/TW3/V
MA/@MJ.HWUW(L%K96-E\2/#5Q=W=S,Y"106T$<DTTCD+'&C.Q`!-?ZJ&M:7;Z
MUHVK:+<EEMM7TR_TNX*?>$&H6LMK*5/9@DK;??%?Y=O[<?[('Q-_8D_:(\;_
M``A\>Z#JFF:=9ZQ=ZE\._$[V]P-&\8^![N[GE\.Z]H.J[?LUZ!:J+348X9FN
M=,UBTO\`3;Z."]M)HE_IGZ/&,P=:'%W#];$4Z&+S3"X:>%C.24JL(4\50KNG
M%VYY4G7I2<4^9QDW:R;7\^^..&Q5*KPSG-*A4K8;`8C$1KRBFXPJ2J86K24V
MHOE5149I2=DFDMVD?ZD<;!D0KR"J\CZ#GZ?2GU_F?>#O^"P/_!2GP'X9T;PA
MX:_:Q\>0Z%X?LH=-TF'5]'\#>)[ZWL;==EO;2ZWXG\*:QKEZEO&!#`;[4;EH
MH$C@1EBC1!TG_#Z[_@J)_P!':^*C]?!'PG_IX!%>9/Z./%JE)0S7)I04GRR<
M\3%RC?1N/L7RMK=7=GI<]"EX[<-^SI\^6YI&?+%2BE0DE*T;I2]HKV;:6BO:
M^ES_`$G:*_D;_P"""?\`P4._;+_:S_;"^(OPX_:'^..M?$OP5HW[-WC'QKIN
M@ZCX=\$:1!:^*--^)OP?T.QU=+GPUX8T6^>6WTKQ'K=FL$UU):,E^\CP--%!
M)%_7)7Y!Q?PKCN#,[K9%F-;#U\51H8>O*IAG.5)QQ--5().<82ND[2O%:GZA
MPMQ)@^*\IIYQ@:5:CAZE:O04,0HJHI4)<DG[K:LWMK?R/Y*O^#I7Q\(_"W[*
M?PNBFPUWK_C_`,>7T'F#+K8Z=H_A_2Y?+#;L1M?ZN@9EVGS2%;*LIT_^#6[X
M>FV^'_[4OQ3FA`.J^+O!'@BPGV\O'I&D:CK.I1ES&.(GU73F"I*X_>Y=$.UF
M^"O^#F'X@GQ%^VYX`\"+,\L7P\^"6B2-'N8QV]YXMU[7-1FC52=JRFUL;*:0
MJ.4ECR200/WC_P"#=GX:GP/_`,$VO"'BB2`Q3_%WXG?%#QZS2#$LEOINO#X;
M6AP79UA*>`&G@5UB#+<-<1QLEPL\W[EG5LD^CUDF%MR5,]QU"<D_=;=?&5\P
MNE+67-0PL-NCYE='X[E/_"OXVYKB/BAE&&K*-M;>RPU'"-/MRUL1*VUFMKO3
MX=_X.?OV>!K/P[^`W[3NE6(-[X+US4/A1XJO8X_F;0O%`FU[PV+F0`DQV6LZ
M?JR6H;:L;ZO='):55K^;'1OVV/&.F?\`!/\`\7?L-,]^V@ZW\>]#^*VG7PE#
M06_A_P#L"YB\1>&26E#P6K>*=)\.:_9VD,303W6H:]<W#QR^2LO^AA_P41_9
MPMOVL/V,?C[\$O(CEUSQ%X%U'5?!4CD)]F\?>$]GBCP5)YQ*F""?Q#I-C8:@
MZ,I?2[V^@?=%+(C?Y>%S;W%I//:W4$MM=VTTEO<6T\;PSV]Q"YBE@GBE"O%+
M%*K1R1R*KHZLKJ""*^R\"\;@>).#XY+F<8UZW"F<TL=@U4:O1A*H\9@ZT>J5
M.O\`6J=[VY'*#]W0^6\8,'B\BXJEFF!E*C1XBRRIA<0X)I5)<D<-B:4MK\]-
M49I+7F7,M6?UO_\`!K]^S?)-??M!_M7:WIY^SVD6D_!3X?W<H4J]W+Y/BSXB
M7,<;J65[>V/@:QM;N(X=+[6;0G*2I7TE_P`'07PSCUS]E[]G_P"*\-MY]_\`
M#OXUWOA.2953=9Z#\2?!^IWFH3M(S*5B?6?`/AFV:*-7:26XA<A4A9A^K7_!
M)_\`9[7]FO\`8(_9\\`W-C]AU_6/!UM\0_%<;QB.X/B+XA?\51>1W2E5D2XM
M+?4+2QDBFS+;FU%LVT0A%\6_X+L_#]O'W_!,WX]K'#YD_@U_!GCR"0('DA7P
MSXKTNXNY$^5BNZQEN8';Y?W4T@W+NR/R-\7O,O&_"9]&K;#+B.AEN&FG>,<`
MI?V4I*[LE6I3J59V:UJR:ULC]-7"ZP'A%B<GE37UB62U,QKQM[TL;*V/L[;R
MA.,*47VA$_'7_@UG^(R1ZY^UK\)+FZ(>XTSX:_$31K/<Q#"VN_$GAOQ)<A"V
MT%#=>%8MRIN8/B1L)&*_K:^(>@+XJ\">,/#;)O\`[;\-ZUIBH>0TEYI]Q!$#
MW_UCKTYK^"3_`(-T/B1_P@__``4?T/PX\XA@^+?P@^)?@!ED*B*2>QAT?XDV
M@)9659C)X`,4#AHW+3-;HY^T-#-_H%$94ANXP?3\?8__`%J\SZ0.41AQUG$*
MD;4L[RS"8BVMG"KA/J%1O97<\-4;2NGO>[9T>#V+CF'`F'PLWS?5,1CL#-=5
M&4_;I6[*&)BEY(_E(^$7B2;X8?&GP'XBN2T3>$O'6EG4QRI^R6VIK9:M$=X^
M0R6;W4+$@%=Y)'!%?U/:E8Z;XH\/7VF72P7VD^(='NK&=&5)[:[T_5;*2WE4
MJP>.:*>WG8%6#)(C$$,I.?YT_P!NGX/3?"KX[^(+VTMFB\,_$":7QCH<J*?*
MBN]0E,NOZ>IP%0VFK-/-!%&-D5C=V:+RK*OZN_L'?M`6GQ=^%%CX6U:ZC'CC
MX=VMIHFK02R+YVIZ3#'Y6CZ]`I(9UE@C%G?[1^ZO[>1RL<5U;!O\YO`',Y<%
M\9<7^&V:S>&Q7]HSQ>5*H^55:N$;A.--NUY5\'[#$0L_>C2?+?<SX!Q/]C9S
MG/#6*E[.JL1*KA>9V4Y4KQDHO2\JE'V=6/=1=C_.O_;(_9U\2?LF?M-_%SX%
MZ_9W-D_@;Q?J$?AVYF$N-4\(WLQU'PCK5I-*`]Q;W^AW%E,DYRS2B5),2I(J
M_P!V?_!'K_@HUX+_`&U_V>O#?A/Q#XELX/VB_A5H6G^'?B/X6OYO*UC7['2[
M:"QTOXB:6L@5=5TS7H(T&JR6C23Z9KD=[#J$%M!<Z9<7W*?\%BO^"5MI^WQ\
M/=.\?_#"'2M(_:5^&FE7EMX6N[QX-/M/B#X=#2WO_"`Z]JDFR*V9;UYKGPQJ
M=^_V32=0O;R*YEM;#4;R>/\`A)MKO]H#]D+XQL]M-X_^!/QK^'.LO%)L-_X8
M\3Z'J%G.4DCD7Y%O=/N6B8,KB\T;6;)LXO;"XS)_K_263>.G!."P<\;1P'%^
M10AS>TM*:K<D:-2JZ>E2K@<>H1G)TM:5:,;W=/EE^X>YBZ25[5(V^3V;\T^O
MR\F?ZM%)D>O6OX@O@I_P<S?M/>#?#MCH?QF^$'PZ^,6IV5NENWC'3KR\^'VM
M:F8X]HN]7TS3+/4O#TM[.^&N)-'T_0[+D^1IT?2I?C+_`,'-/[3/B[0+O1_@
MW\&_AQ\)M3O+5K<>+=6OK_Q_JVFO("&NM*TR^M=)T)+N'K;OJMGK%GO^:>PF
M4;#^/_\`$"?$7ZY]5_LW">RY^7Z]_:&'^J<M_P")\7UGEMK;ZMS]HLY?J=:]
MO=];]#^Q;Q7^T)\$/`OQ(\'?!_QA\4_!/AKXG_$&VOKOP7X(UG7[&PU[Q'#I
MQA6Y_LZTGE0R2GS@;6W=DN+\1736$5RME>&#V($$9'2O\K/3KS]IK]L3X]V%
MW8:A\2/C7\?_`![XAMY;#48;K4M7\4W&K-/YT%Q!=Q.J:%INDX\Z*2)].T;P
M_86^^/[#8VG[K_23_88^&_[1'PF_9E^&W@7]J3XGP?%KXQ:-IKQZ]XG@M8D-
MI9,X&C^'+G5D2*7Q5>Z!8+'8WGBN]@AO]:G5Y[LW,BF^NN3Q%\-</P%@\IE+
MB'"X_,\9%QQF6Q@Z=:E*TF\10BN9O"1:5'FK^SG.IK"Z;C!5\.J,8OVB<GO'
MKTU6FWK^FOPE_P`%Y/V7-=_:1_80\5:MX+TB?6O'/P+UNQ^+6E:;:1M+?:CX
M<TN&>P\>6EE&N3)<6OAB\NO$2Q*IEN!X?-I;J]Q<QQM_%W_P3=_;#N/V'/VL
M_AS\<;BTN]5\'0RW/A3XDZ18%3?7_@'Q)Y5IKDVGQR,D,VJ:.4MM<TZ"62%+
MNZTU+%[BVCNI)X_].2YMX+RWGM+J&*XMKJ&2WN+>>-98)X)D,<T,T;@I)')&
MS(\;@JZL58%217\/G_!7K_@B9X[^"7BCQ?\`M(?LJ^%M2\:_`[6K^]\1^+_A
MWX>LIM0\3?"2ZO9Y+O4+C2](M%EOM:^'\<CRW"7%G!+=^%;0F/4XFTJV;5(_
MMO!GC'):F59IX=\45:='+\X=;ZA7K35.E*>,IQHXC!RJMI4JDY*-7#2DTG5<
MX7YG!2VPE6/*Z,W:[TOUOHUZ]KOT/[4_AS\1?`WQ;\%>'?B)\./$ND>,/!?B
MO3;?5M`\0Z)<QW>GZA97*!T=)$^:.5,F.YM9ECN;2=9+>YBBFC=%[8@?W1^7
M^<?6O\QS]CC_`(*1?M;?L(ZM<1?!;QY(/"%U>-/K_P`)_'%G/XA^'NJ78`26
MX?09KFSO-!U1@J+/JGAK4-#U2X6&&"]N;FVB6WK]F++_`(.B?CS'I"V]_P#L
MO_"R[UORMK:K;>-?%%EIYFP/WHT>33+N94R#^Y.K,?F'[WY>?(S[P`XQP6-G
M')%A<ZRVI4OA\1'%4<+7C2D[Q^L4JTX14H*RE*C.I&=FXQ5^51/!U$[TW&4-
M;:ZK7;S]3^TM3GMC'\^_:EK^*[]E;_@XD_:%\6?M=>!O^&E&^'_AW]G3Q:[>
M"M9\,^$/#2:99^"[W6[ZR31_B!<^(M3GU?Q-?3:-<QK::O%<:O!H']BWVHW@
MTBWN[:WNH?[2[:X@N[>"ZMI8[BWN88YX)X762&:&9!)%+%(I*O'(C*Z.I*LI
M#`D$&OS?B[@C/N"<5A,+GM"E3GC<-]9H5,/5]O0DE+EJ4O:J,4ZU%N/M8JZ2
MG!J4D[F%6C.DTI6U5U;7U1YS\:?^2.?%C_LFOCK_`-1C5*_RF?!%Q!9^,_!]
MU=2I!;6OBCP]<7$\AVQPP0:M9R2RR$_=2.-6=B>B@FO]9GQ%HMGXD\/ZYX=U
M`,UAKVD:EHM\J'#&SU2SFL;H*3G#&"=P#@X..*_S#OV[OV,?BG^Q'^T!XT^%
M/C_P[J-KX?36;Z_^''C%;.X_X1SQOX*NYWN-$U71=4\L6D]Q!921V.M:>DIN
M]'U:WN["[16C1Y/V[Z..88&-7BG):^)IT<9F5#`U<+3G*,9UJ>'CC*5?V2E\
M<J?UFG)QC>5G?8Z\#)+VD6]7RM?*_P!^^Q_I[Z-JVF:]I.F:UHU];:GI.K6%
MIJ.FZC9RK/:7UA>P)<6EW;3(2DL%Q!(DL3J<,C`UIU_ED>"OVW/VQ_AOX>T_
MPE\/_P!JG]H7P5X7TF!+;3/#OA;XP>/=#T73[=,[(++3=.UVWM+:%-S;8X8D
M1<G`&:ZO_AXO^WY_T>I^U-_X??XE_P#S25SU?HU<0*I4]AQ%D\J//+V3JT<;
M"HX7]WVD84IQ4[?$HSDK[,3P,KNTXVZ:,_U#*:QRC$?W6_D:_P`_;_@E?^W!
M^V5\2?\`@H-^RYX%^(7[57[0GCCP7XD^(%Q8^(/"GBSXO>/-?\/:W9+X7\07
M(M-5T?5-=N;"_MQ<00S"&Z@EC$L4;A=R*1_H%,,J1Z@CT[5^2<=\#8[@#-<)
ME>88W"8ZKBL%#'QJX.-94XTY5Z]!0DJT(2YU*A*3LFK-:WNES5:3HSBI-.]I
M75]K_P#`/\C+4?\`C^OA_P!/=R/_`"*]?ZPOP<\5:#XW^$WPS\7>%]2M=8\/
M>)/`7A+6='U*RGAN;:\T_4-"L;BWFBF@DEA?,;@.$D;8X9&.Y2*_S?/^"E_[
M#_CC]AW]I[Q_X$U+1-2'PO\`$&OZMXF^#GBY[6=M)UWP/JU_<7>EZ8-1V?9G
MU[PU#*NB:[9B03I=6@O?)2TO;5G^?_AQ^V!^U=\'O#\7A/X4?M*?'3X;^%[=
MF>W\.^!_BIXU\,:+`SL7<PZ9H^M6=G%N=F=MD*Y9B3R:_JOCO@B'BUD/"V8Y
M#G.#HQP>'JU:-2O&=6A6HXZEA/:0FZ'/4I5Z,\+&+A*FVI<\)\DHGH5J2Q$*
M;A*R6JNM+-+U[=S_`%3**_R\_P#AXO\`M^?]'J?M3?\`A]_B7_\`-)7U!^Q%
M^WI^V[XP_;1_9#\)>*_VNOVD?$OA;Q3^U!\`O#GB7P[KOQH^(6J:)K^@:W\5
MO">F:SHNL:9>^()K/4=*U73KJYL=0L+N&6VO+2>:WGCDBD=3^08_Z.W$67X'
M&X^IGV2SIX+"8G%SA"&.YYPPU&=:48\U!1YI1@U&[2NU=V.=X*:3?/'3R9_H
MV54MK^QO'N8K2\MKF2SG-K>1V\\<SVMRJ)(UO<K&S&"=8Y(W:&4+($=&*A64
MFRYVHQP3A2<#J>.@K_-=^.7[=G[6_P`,_P!M?]HKXN_#'XG?%KX(Z_XL^+GB
MW4G\/23ZKH\4FE66L75AH%IXE\#^(K>31]0,.DVMIYEAKFB744<N\&$$"OSK
M@'P_QO'V(S/#8+'X7`U<NPM+$1>*4G"O4JU'"%%<CYXWC&<G-1FHM13C[R9A
M1HNLY)-1LM+ZWVN?Z4?&>ISD<9Z?AD?CUK^57_@Z'TCX5CX3?LSZ[<?V7%\:
MA\1_$.EZ+Y8B36+SX9/X8O+KQ2;S8!-/IVG>*8/!@L#<LT=M<ZEJ`LMK75[N
M_);3O^#AO_@I78Z`=&N?&WPNU?4#'Y8\5:E\)_#T>OJVP+YRP:3)I?ACS<@R
M$-X<:'>S?N@@1%_,KXJ_&3]IK]M[XN0>(_B3XC\=?'7XL>)9XM*T:PL]+.H7
MA$\X%MHGA3PCX8TZWTS1[$SR#R=)\/Z196GFNTGD>8[N?VKP]\&.)N%N*,#Q
M#GF897@L#E3K5I/"XR=2>(YJ-2E[.4IT:,*5!J;E5E4E=QCR\EWS1ZZ&%E3J
M*<Y+EB^F[_R[6/GVST[4M0\S^SK*\O/)V>=]DAGF\OS-_E^9Y*-MW[)-F[&=
MC;<X."O[M/\`@D7_`,$?]*_9X^!>N^(/VJO!.@:U\8/BU?:'K5_X4ODT[7(_
MA[H&B6VIIHGA^6[5;NR;7)_[:O;[7_L$DD$,[VVG_:;IK#S:*VXG\:\CP^?9
ME0P6"698:A7C1IXZDX.GB'3I4H5)TY->]356-2,)[3C&,EHU=5,3!3DEJD[7
M7HO^#_6_[S>-/A[X$^)&CR^'OB!X.\,^-M#F#B32O%.B:=KMB?,7:S"VU*WN
M(D<KQYB*KX`^;@5\,>)O^"27_!.'Q9=F^U7]D;X20W3RK-))HNCW?AY99%#C
M,L>@WVG1RJV\[UD5D<A"ZL40C]&**_F#!YQFV7)K+\SS#`IO6.$QN(PT7YM4
M:D$WZH^>Q>597CW?&Y=@<7+^;$X6A6EZ*52$I)>2=CY"^%/[`O[%_P`$;^'5
M_A;^S/\`!_PAK%NP>'6;'P9I5QJ\;J_F)(FHZA!>7B2Q/S#(DP>(!1&RA1CZ
M\`"@```#H!2T5ABL;C<?4]MCL7BL95V]KBL15Q%2W;GK3G*WE>QOA<%@\%#V
M>#PN&PE/^3#4*="':[C2C%-^;5PHHHKE.D\V^+'P=^%GQV\&7OPZ^,G@+PQ\
M2O`NHW>GW]]X4\7Z7;ZQHEW>:5=)>Z=<SV-RK1/-97<<=Q;N1F.5%=>17B?P
MK_8-_8S^!_C;2_B1\(/V:/A!\.?'NBPZC;Z3XM\)^#M,TC7-/AU:PN-*U.*U
MO[:-9HDOM.N[FRN54@2V\\L;?*QKZUHKLI9CF%##U,)0QV,HX2MS>VPM+%5Z
M>'J\\5&?M*,)JG/GBE&7-%\T4D[I(XZN7X"MB*>+K8+"5<52Y?98FIAZ,Z]/
MDES0]G6E!U(<DO>CRR7*VVK-L****XSL`C/!KR;XM_`?X,?'K0D\,_&CX7>!
M_B?H,3M)#IGC7P[INO6]N[[=[VWVZ"5[9I-J^8T#QF0*H?<`*]9HK6C6K8:K
M&MAZM6A6@^:%6C4E2JPEWC4@XRB_--,RK4*.(IRI8BE3KTIJTZ5:$:E.2[2A
M-.,EY--'P/\`\.L_^"<_7_AC#]GW/K_PKS1O_C-)_P`.LO\`@G/_`-&8?L^?
M^&\T7_XS7WS17I_ZQ<0?]#W./_#GC?\`Y>>;_J_D/_0ERG_PW83R_P"G/DCY
MC^"_[%W[)_[.GBF_\;_`K]GWX6_"GQ=J>@W7A;4/$7@CPKI^AZK>>';[4-+U
M:[T:XN[2-))-/N-2T32;V6W8['N-.M9"-T2U].445YV)Q6*QE5U\9B:^*K-1
MBZV)K5*]5QBK1BZE64IM16D4W9+1'H8?"X;!TE1PF'H86BFY*EAZ4*--.7Q-
M0IQC%-[MI7;U>I\F_%;]A+]C?XY^-+_XB_&']FSX1?$CQUJEM86>H>*_%WA#
M3=8UN\M=+M8[+3K>>^N8VE>*RM(H[>W0G$<2A5%>_P#P\^'7@7X2^#-`^'7P
MS\)Z'X&\"^%K1['P[X4\-6$.EZ'HUG)<SWDEOI]A;JL-O')=W-Q<NJ*-\TTL
MC99V)[.BM*N/QU>A2PM?&XNMAJ'+[##5<36J4*/+%PC[*C.;IT^6+<8\D5:+
M:6CL12P."H5ZF*HX/"T<36NJV(I8>E3K5>9J4O:5804YWE%2?-)WDDWJ(RJZ
MLC`,K`JRD9!!&"".X(ZU\,:E_P`$R/\`@GSK&JZAKFJ?L>_`2_U?5=1NM6U'
M4+GX?Z-)<WNI7US)>7=[<2-#F2XN+J62>5SRTCLQZU]T4487'X[`^T^I8W%X
M/VJ4:OU7$UL/[6,;\JJ>RG#G2N[*5TKNV[#$X'!8WV?US!X7%>R?-2^LX>E7
M]G)V;</:PER-\JNXV>B(XHHH(HX88TBAA18XHHU"1QQHH5(XT4!41%`554!5
M4```"N9\;^!_"'Q*\)Z]X$\?>'-)\7>#?%&GS:3XB\-:[9Q7^CZSIMQCSK'4
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ME^SS8?M"?#*\T2#R;3QCH1?5_!NJ2*,0ZE$G[W3KE@-QL-6@4V<XS^XE:WO`
MKM;"-_Y\/`?CCXB_LX?%!=8TP76A>*_"FJ2Z9KVAW\;I#?0V]RJ:GH>K6KA6
MDM;M$,1==DT),5W9S0W$<$Z?U8U\.?M7_L8>&?C]9S^)O#K6?AGXH6D"BVUA
MH2+#Q!%`F(].\0K"OFL0@6&TU1%FN;-0B/%=6R+`O\W>,WA3F'$-?"\:\&SE
MA>,,G]G4<*,_8U,RIX=\U%TJETEC:%N6FYOEK4OW,GI!'PW&7"N(S&I2SK)Y
M.CG&#Y7:#Y)8F%.SARRT2KT]5%R=IPM3>T;>L?L^?M+?#_\`:$\.1ZAX<OH;
M#Q'9PQ'Q#X1OIT76-)E<!3(L;",WVG2296WU&V1X'.(I?*N`\2\=^U#^PC^R
MI^V-HYTOX_?"/P]XNO883!IWBRV%QH/C?1P`?+.F>+M$FL=;A2)CO6SFNY]/
MDYCN+.:&22)_P*\4>"_C%^SIXU@&KV7B+P%XET^=GTK7+*2XM;>]$94F?2M5
MM_\`1=0MV&P31QRR`*XBNHE)V5]J_"K_`(*:_$SPS!;Z9\2_#6F>/[")4C&K
MV$Y\/^(PH`!DNG$5YI>I%5'RHMEILKL2TMXY/'F\`_2863UZ.7<<T\SX3XER
M^2HU,UPU/$4:<ZD+1=2M2I6Q.$J27O5%&-2A/5PM%J"X\F\1:5)K!<14JV6X
M^C:%2O[*?LIR5DW4IQ3J49/>2490=KJR:BOD7X@_\&NWP1U769[KX8_M1?$[
MP3HTTTDL6D>,/`_ACXAW-K&[2-]GAU72]6^'A>*+=&D#W-E-.(X\3RW$KF86
MOAM_P:]?`71M6CN_BM^TQ\4_'NE13))_9/@WPCX8^&[7$:8)M[O4=2O_`(B3
MM#*05D:SBL;CRCB&>&0B9?UOTC_@IU\!+Z`/J>D>.=$F"_/!<:3:7A#@@%5?
M3[ZY5AR2&.W@<@$XJQJ/_!37]GVTMFELK+QOJLPW8M;?18;:1CQ@![Z\MH><
M\9D`&#DCC/\`3"^EO2GA$EXMX=473M?VE%5^6R7Q_4EB.:VE[\^NFK/M%QMD
M+ASK/,):W-?G?-LG?E<>:_=6OY7/:?V8_P!B7]F']CO0GT+]GSX2^'O`WVJ!
M+?5=?076L>+M<52K$ZWXKUNXU#7K]&D42_9Y;[[)&X406T4<<:)WGQN_:`^'
M7P%\-2:]XUUB-+R>.5-$\.VTB3:WKEV@R(;*S!WB)"5-S?3".SM591++YDD,
M<GY5_%/_`(*?^-]=@GTSX5^#['P;;R^9'_;_`(AG77=;V,`5DL]/@6VTK3IQ
M\RLUR^MHRDF,02!7'PQHOAOXT?M+>.)FL(/$?Q"\57KJ=0U2[DFN+;3K=W(#
MWM].PLM+LHB6\J'?#&<,EO"[Y2OYMXZ^DOA\QQ%;`\$T\QXPXGS"?LJ>8XBE
MB:U"%66D:L8U4\3C9Q?P0M"DK7E/E7*_C\W\1</)O"</TJV:YA5]RG5]E4=&
M,GHI1A;VE9KI'EC%6UDUH_TV^!/_``4DC\0_$#7-(^,5KI_AKPKX@U19/"&J
MV<3&W\+P%(+:'2=<N$7S+JUF\L7LNLRQJ;>]N+P2K#IGV:&P_6FTO+/4[6&[
MLKFWOK*ZACGM[JVEBN+>Y@F0/'+#+$6BDC=&5D=&965@02#S_.Q\7_V!_C5\
M*O#VG>);6W@\>V)T^.Y\00^%;6ZGOO#]YR9X/L1#76IV$*[3_:-K$I/[QIK.
MWBB\U_-?@W^U?\:O@88K#PMXA_M#0()BTGA+Q/'/J>BKM8"6&"'S[>]TW)'S
M#3KNT`?+%26??\9POXU\7\!8MY%XMY1FCA7F\1ALW]@OK5*->2J.$HPM1Q="
MFYVBZ$_:T$O9.,THJ/DY7QIFV0U?J'%V#Q2YY.I2QC@G5A&HU)QDH^Y5IQOI
MR24Z=N1IZ*/ZG?M,?\$B?V"_VJ;N_P!=^('P5T_PYXTU$N\_CWX97EQX"\4/
M<R##7=W_`&0/[!UFY]'\0Z%J\8.6,98DU^8.J_\`!K]^RO+J(DT7]H;]H.PT
MG<A-GJ<7PXU?42@<EU_M.T\'Z);!FB(17_LC"R`R%'4^6/T-\%_\%3_!EU;P
M1>/_`(<>(=%OL*DUUX<O['6M,=N`\PBO?[*O;96.66`+?,JG:9W(W'UE?^"E
M?[.;!6,GC!3@$I_PC\IVDC)4E9B"5Z9!(XR"17]5</?2FRC"8*G'*/%*6#PW
M+%1PN*Q-:,J"LDJ:HXVC-TN5:<M.T5KRZGZ#A^-^'ZM-2IYUAXII/EJRG3G&
M^MG&I%23Z/=;JY\L?`#_`(($_P#!/'X'7ECK>J^!_%OQS\1V$J3P:E\9O$R:
MSIL,X(8F/PEX:TWPIX1N80Z@PQZSHNKS0``K<L^Z1_V?M;6PT?3K6PLH;73=
M-TRT@M+2U@6*VM+&QM(5AM[:"-`D4%O;P1I%#&@6..)%50%`K\Q/%G_!4;X;
MV5O*G@GP'XJ\1WPSY+ZM<V'A_3">0#),G]JWQVX#&-=/`=3@2HW(^#_BK^V%
M\9_C2+G3]6UF+PWX:N"RGPSX66XT^QF@8X2+4;M[B:_U)BF%F\V>.VE;>4M(
M8V\E?@N.?I0<-5Y.M6XBS#C;-(J7U>AAZE>K0A)V33Q%>,</AX-VYW1A-NVD
M)25CRLS\0LBPT;4<5+,\19J%+#*3A=?SU914(J[U<5.6^FQ_1LDB2('C99%(
M!5D8,&!Z$,N0?7(KS;XI_!GX3?&[P^WA3XO_``Z\&_$CPXS^:-'\9:!INO64
M<N,&6"/4+>8P2%?E:2!HW9?E8D<5^(_P3_:H^+?PL@M-+T[64U_P[;^7&GA_
MQ()]0M((`H7RK&Y6>&_L%13^X2&Y-M$0BFVDB7RZ_1?PC^W/X1UJ"%/$?A'7
M-&O&4>8VGW-IJUB#CDK(XT^ZP2.$-HV!UD)Y,\)>./">=1HU9XS$\/9G#E<J
M6)]K#V56V]#&4$DUK[LG[*5M7&+T-LJXUR?'PBZE6>!Q%ES4JRE92Z\E6"<9
M+M?E?=+4K_\`#K?_`()V?]&:_L__`/AO-$_^,4?\.M_^"=?_`$9K^S__`.&\
MT3_XQ7MEC^TY\-M1*_9VUKYAC#Z:ZCUZ[\=".GK710?&;2=2(72=+O96;`$E
MV\5O&`<'.U3-(V,_=*QYQ]\5^K4O$AUTG0XPQ]>]K*EFN.FW>VR57S6Y]%#-
M\)4_AXZ,^RA.4F]MK>J/(OA__P`$^/V(_A5XRT#XA?#?]EWX,^"O''A:\;4/
M#GBGP[X)TG3M:T6^:WFM6NM/OH(5EMIS;7$\)D0@^7*Z]&-?8@&,\GGU[?2N
M6\/:K=ZIF:YVC*Y"1J5C7(/W02S$]/O,?;L!U5==3,L5FO)B<5B\5C)*/)"I
MBZ]7$35--R48RK2G*,>:3?*FDFV[7;.M5/:I3YI23V<FV[;]3SGXF_"#X6_&
MCPY+X0^+/P^\(_$7PQ,69]$\8:#IVO6`=EV-)%#J%O.()F3*&:`QRE"5+E3B
MOD__`(=;_P#!.S_HS7]G_P#\-YHG_P`8K[VHKKPV;9K@J;HX/,\PPE)R<G2P
MV,Q-"FY/>3A2J0CS.RN[7=BU.:5E*2792:7X,^"?^'6__!.S_HS7]G__`,-Y
MHG_QBM[PK_P3?_8.\#^*/#?C7PA^R=\#_#GBWP?KVC^*/"_B'2?`FCVFJZ#X
MB\/ZA;ZMHFLZ9=QP"2UU#2]2M+:^LKB,AX+F"*5"&4&OMBBMI9_GLXRA/.LV
MG"<7&<)9CC)1E&2M*,HNLU*,DVFFFFG9Z#]I4_GG_P"!2_S"O`OB_P#LK_LX
M?'Z-H_C/\$OAI\269=ANO%?A'1]3U`)M"*%U.6U&HKY8`\K%U^Z(!CVD9KWV
MBN##XG$82K&OA<17PU:'PUL/5J4:L?\`#4IRC-?)HE-K5-I]T[?D?EK/_P`$
M6?\`@F5<ZE_:;_LJ^$$F`<""#7_'-MIQ\PLQSI5OXICTXE2Y"$VQV`(J86.,
M+]@?!K]DG]F7]G@!O@I\#?AK\-[C88SJ'A?PII=EJSJP8.'U;R'U-_,#,)=U
MV?,!(DW#BOHJBO1Q?$.?X^DZ&.SO-L90=KT<3F.+KTG;:].K6E!VOI=%.I-J
MSG)KU?X]_F(5!ZBBEHKQR`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`I#T/T-%%`'+^*/!GA3QUH\^@^,?#VD>)='
MN3^]T_6;"VO[8OM(65$N(W\J>/<3%<1%)H6^>*1&`(_./XU?L&?`"VM;G5]!
ML?$_A>=O.F^S:)KJ&R4HA8(EOK&GZMY<9(Y".&QT8445^->+^391B\DJ8K%Y
M5EN*Q4/=AB<1@<+7KPCR_#&M4I2J17DI)'R?%N#P=;+YU:V$PU6K&RC5JT*5
M2I%76D9RBY)>29^-/C[PU8^%M>DTO3YKR:W2(.'O'@DF),DB\M!;VZ8PHZ1C
MG/-+\/\`PQ8>+->32M1FO(;>0)N>R>"*?F2-.&FM[A.C'&8SSCW!**_AV.7X
M#ZXH_4<)R^U:Y?JU'EM?:W):WD?A?U?#^V2]A1M[2*M[*%K76EN4_9'X)?L'
M?`&ZMK36=>L?$WBF?RX+DVNN:Y$+!F=0S1O;Z/I^D^9%EONN[-@#YNI/Z/\`
MA+P5X2\!Z1#H?@WPYH_AK2+<_NK#1K"VL;?<6PTLBP1H9IY/O2W$QDGF<EY)
M&<EB45_<?@]DV3X3(:>+PN59;AL5.*C/$X?`X6CB)QM%\LJU.E&I*-];.35S
M]RX2P>#HX"G5HX3#4JLHVE5IT*4*C7+#1SC%2:\FSIG&6`/(.,@\@\]QTKYG
M^+'[)OP&^*DESJOB;P+86^N3^9+/KWA\G0M6N)2"QFNY[!8XKV<G&9[V"XFP
M%3S-@"T45]]Q9EN79EDN-I9C@,%CZ<*%2<*>-PM#%0C-))3C"O3J1C)+:22:
M[GOYGAL/B<)5AB</1Q$5&ZC7I4ZL4[K5*I&23\[7/QW_`&B_V9O`'PJ>27PQ
MJ/BJ17BNYU@U34-+NH8C"<(D9@T6TG*`=?,FD<_WZ^#\G!]@N.F.<9HHK_.[
MB'+,MHYEB(4<OP5*"K22A3PE"$4N9:*,::2^X_G?,<-AX8NK&.'HQ2>BC2II
M=>BBD?>_[.'[,_@#XJ)%<>)M0\51@"TD:#2]0TRUAD\U4+JYFT6ZG"_,0/+F
M1@,?-Z_L5\*_V6O@=\*Q:ZAX8\$6$NL0!6AUS7"=;U:%V4DR6US?"1+27!*B
M6TB@DV,R%RI(HHK^B/`K(LDJ59XBID^53Q%.*G3KSR_"2K4YJ,;2A5E1<XR7
M249)^9^A\#8'!2<JDL'A74BHN-1X>DYQ=J>L9N',GYID7Q$_9;^"7C-KK5K[
MP=:Z3JTI:XFU'PVW]ASSSL2SRW$5H@LYY9'R\LLMJTLKDM*[DFO@CXA_!WPO
M\/KN9-$O-<G2.)Y474KJQG"_)(X0&WTVU8H"H`W,6QU8GFBBOHO$C*,IP^90
MJT,KRZC4J6G4J4L%AJ<YR:NY3G"E&4I-[N3;?5GH\2X3"4\0IT\+AX3EK*4*
M-.,I-MW;DHIMOJV[LI>$QAH_JWZ8%?>7PR\(:7?6]O<SRWI;;&=B2Q+'D\?\
M^YDZ?]-***[>"Z%#GH_N:6R_Y=P_N^161PASKW(_&OLK_(^F+'3;/3K<1VL6
MP``98EW."!RQYR<<UI445^^4DHTX**226B222^2/T"*M%):*R_(****T&%%%
0%`!1110`4444`%%%%`'_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
